Urantide Conformation and Interaction with the Urotensin‐II Receptor

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Archiv der Pharmazie

• Publication date

  2014-03-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1002/ardp.201300269PMID 24357333
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The effect of d-amino acid substitution on the selectivity of temporin L towards target cells: identification of a potent anti-Candida peptide.

  2013cited by this paper
• New insight into the binding mode of peptides at urotensin‐II receptor by Trp‐constrained analogues of P5U and urantide

  2013cited by this paper
• The urotensin II receptor antagonist, urantide, protects against atherosclerosis in rats

  2013cited by this paper
• Endogenous Urotensin II Selectively Modulates Erectile Function through eNOS

  2012cited by this paper
• New Insights into Cardiac and Brain Sodium Channels Modulation by Beta Blockers

  2011cited by this paper
• Discovery of a potent and efficacious peptide derivative for δ/μ opioid agonist/neurokinin 1 antagonist activity with a 2',6'-dimethyl-L-tyrosine: in vitro, in vivo, and NMR-based structural studies.

  2011cited by this paper
• Potential Clinical Implications of the Urotensin II Receptor Antagonists

  2011cited by this paper
• Conformational study on cyclic melanocortin ligands and new insight into their binding mode at the MC4 receptor.

  2011cited by this paper
• Novel octreotide dicarba-analogues with high affinity and different selectivity for somatostatin receptors.

  2010cited by this paper
• New insight into the mechanism of action of the temporin antimicrobial peptides.

  2010cited by this paper
• Urotensin-II receptor modulators as potential drugs.

  2010cited by this paper
• New insight into the binding mode of peptide ligands at Urotensin-II receptor: structure-activity relationships study on P5U and urantide.

  2009cited by this paper
• Novel sst5-selective somatostatin dicarba-analogues: synthesis and conformation-affinity relationships.

  2008cited by this paper
• Nonpeptide Urotensin-II receptor agonists and antagonists: review and structure-activity relationships.

  2008cited by this paper
• High-Resolution Crystal Structure of an Engineered Human β2-Adrenergic G Protein–Coupled Receptor

  2007cited by this paper
• High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor.

  2007cited by this paper
• A semiempirical free energy force field with charge‐based desolvation

  2007cited by this paper
• Urotensin-II receptor antagonists.

  2006cited by this paper
• Morphiceptin analogues containing a dipeptide mimetic structure: an investigation on the bioactive topology at the mu-receptor.

  2005cited by this paper
• Urotensin-II receptor ligands. From agonist to antagonist activity.

  2005cited by this paper
• Human Urotensin II Is a Novel Activator of NADPH Oxidase in Human Pulmonary Artery Smooth Muscle Cells

  2005cited by this paper
• Androgenic down-regulation of urotensin II precursor, urotensin II-related peptide precursor and androgen receptor mRNA in the mouse spinal cord.

  2005cited by this paper
• Unraveling the active conformation of urotensin II.

  2004cited by this paper
• UCSF Chimera—A visualization system for exploratory research and analysis

  2004cited by this paper
• Urotensin-II is present in pancreatic extracts and inhibits insulin release in the perfused rat pancreas.

  2004cited by this paper
• Urotensin‐II receptor peptide agonists

  2004cited by this paper
• Structure-activity relationships and structural conformation of a novel urotensin II-related peptide.

  2004cited by this paper
• Intracerebroventricular administration of urotensin II promotes anxiogenic-like behaviors in rodents.

  2004cited by this paper
• Urantide mimics urotensin-II induced calcium release in cells expressing recombinant UT receptors.

  2004cited by this paper
• Structure–Activity Relationships of Human Urotensin II and Related Analogues on Rat Aortic Ring Contraction

  2003cited by this paper
• Functional and Binding Characterizations of Urotensin II-Related Peptides in Human and Rat Urotensin II-Receptor Assay

  2003cited by this paper
• Urantide: an ultrapotent urotensin II antagonist peptide in the rat aorta

  2003cited by this paper
• Identification of urotensin II-related peptide as the urotensin II-immunoreactive molecule in the rat brain.

  2003cited by this paper
• Human urotensin-II as a novel cardiovascular target: 'heart' of the matter or simply a fishy 'tail'?

  2003cited by this paper
• Crystal Structure of Rhodopsin: A G‐Protein‐Coupled Receptor

  2002cited by this paper
• Designing peptide receptor agonists and antagonists

  2002cited by this paper
• Structure-function analysis of urotensin II and its use in the construction of a ligand-receptor working model.

  2002cited by this paper
• Identification of nonpeptidic urotensin II receptor antagonists by virtual screening based on a pharmacophore model derived from structure-activity relationships and nuclear magnetic resonance studies on urotensin II.

  2002cited by this paper
• Molecular and pharmacological characterization of genes encoding urotensin‐II peptides and their cognate G‐protein‐coupled receptors from the mouse and monkey

  2002cited by this paper
• A new, potent urotensin II receptor peptide agonist containing a Pen residue at the disulfide bridge.

  2002cited by this paper
• Structural requirements at the N-terminus of urotensin II octapeptides.

  2002cited by this paper
• Role of androgens in the regulation of urotensin II precursor mRNA expression in the rat brainstem and spinal cord.

  2002cited by this paper
• Is urotensin‐II the new endothelin?

  2002cited by this paper
• Design, synthesis, conformational analysis, and biological studies of urotensin-II lactam analogues.

  2002cited by this paper
• Crystal structure of rhodopsin: A G protein-coupled receptor.

  2000cited by this paper
• Human urotensin-II, the most potent mammalian vasoconstrictor identified to date, as a therapeutic target for the management of cardiovascular disease.

  2000cited by this paper
• Cloning, sequence analysis and tissue distribution of the mouse and rat urotensin II precursors

  1999cited by this paper
• Urotensin II is the endogenous ligand of a G-protein-coupled orphan receptor, SENR (GPR14).

  1999cited by this paper
• Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14

  1999cited by this paper
• Cloning of the cDNA encoding the urotensin II precursor in frog and human reveals intense expression of the urotensin II gene in motoneurons of the spinal cord.

  1998cited by this paper
• Torsion angle dynamics for NMR structure calculation with the new program DYANA.

  1997cited by this paper
• beta-Methylation of the Phe7 and Trp9 melanotropin side chain pharmacophores affects ligand-receptor interactions and prolonged biological activity.

  1997cited by this paper
• Urotensin II in the central nervous system of the frog Rana ridibunda: immunohistochemical localization and biochemical characterization

  1996cited by this paper
• MOLMOL: a program for display and analysis of macromolecular structures.

  1996cited by this paper
• Water Suppression That Works. Excitation Sculpting Using Arbitrary Wave-Forms and Pulsed-Field Gradients

  1995cited by this paper
• The program XEASY for computer-supported NMR spectral analysis of biological macromolecules

  1995cited by this paper
• Isolation and primary structure of urotensin II from the brain of a tetrapod, the frog Rana ridibunda.

  1992cited by this paper
• NMR of proteins and nucleic acids

  1988cited by this paper
• Functional receptors for fish neuropeptide urotensin II in major rat arteries.

  1988cited by this paper
• Derivation of force fields for molecular mechanics and dynamics from ab initio energy surfaces.

  1988cited by this paper
• Application of phase sensitive two-dimensional correlated spectroscopy (COSY) for measurements of 1H-1H spin-spin coupling constants in proteins.

  1983cited by this paper
• Coherence transfer by isotropic mixing: Application to proton correlation spectroscopy

  1983cited by this paper
• Multiple quantum filters for elucidating NMR coupling networks

  1982cited by this paper
• A two-dimensional nuclear overhauser experiment with pure absorption phase in four quadrants☆

  1982cited by this paper
• Urotensin II: a somatostatin-like peptide in the caudal neurosecretory system of fishes.

  1980cited by this paper
• Investigation of exchange processes by two‐dimensional NMR spectroscopy

  1979cited by this paper

• Role of selective U-II receptor antagonists in modifying vascular function in intact and denuded aortic diabetic rats.

  2026cites this paper
• EXPLORATION OF THE UROCONTRIN A SCAFFOLD YIELDS NEW UROTENSINERGIC SYSTEM ALLOSTERIC MODULATOR AND COMPETITIVE ANTAGONISTS.

  2023cites this paper
• Urantide decreases hepatic steatosis in rats with experimental atherosclerosis via the MAPK/Erk/JNK pathway

  2021cites this paper
• Urantide attenuates myocardial damage in atherosclerotic rats by regulating the MAPK signalling pathway.

  2020cites this paper
• Urotensin receptor antagonist urantide improves atherosclerosis-related kidney injury by inhibiting JAK2/STAT3 signaling pathway in rats.

  2020cites this paper
• Urotensin II and urantide exert opposite effects on the cellular components of atherosclerotic plaque in hypercholesterolemic rabbits

  2019cites this paper
• Functional Selectivity Revealed by N-Methylation Scanning of Human Urotensin II and Related Peptides.

  2019cites this paper
• Insight into the role of urotensin II‐related peptide tyrosine residue in UT activation

  2017cites this paper
• Structure–Activity Study of the Peptides P5U and Urantide by the Development of Analogues Containing Uncoded Amino Acids at Position 9

  2016cites this paper
• An investigation into the origin of the biased agonism associated with the urotensin II receptor activation

  2015cites this paper
• Lead optimization of P5U and urantide: discovery of novel potent ligands at the urotensin-II receptor.

  2014cites this paper